Wednesday 22 May 2013


Life science and analytical reagents are those compounds and substances which are used to detect and create a new substance with the purpose of making them available for test reading and are also known as biotechnology reagents. Such reagents are significant in the areas of research, bioscience, diagnosis and education.


This market is driven by factors such as expansion in the use of reagents in the field of therapeutics, growth in research and rapid commercialization of such products. The growth in the field of biotechnology instrumentation also influences the demand for reagents. With the growing number of maarket players in the field of biotechnology reagents, it is expected that this market will witness rapid development.  

At present, considering the vast scope of biotechnology reagents, the market players are heavily investing in research and development of such products. As a result the demand for life science and analytical reagents is estimated to grow rapidly. Recurrent product development in the areas of pharmaceuticals, agriculture biotech and food will further assist in augmenting the growth of this market.

The overall life sciences and analytical reagents market can be classified on the basis of technology, applications and the end users of such products. The technology segment can be further classified as analytical reagents and life science reagents. Among these, the largest market share is estimated to be of the life science reagents segment. 

The applications market can be further divided into sub segments such as DNA and RNA analysis, protein synthesis and purification, drug testing and gene expression. North America is considered the prime geographic market for the life sciences and analytical reagents industry. However, fastest growth will be observed in the Asian market.

Some of the major players in the biotechnology market are Life Technologies, Thermo Fischer Scientific, Bio-Rad, Water Corporation, Roche, Abbott and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  

This report provides comprehensive analysis of 

  • Market growth drivers 
  • Factors limiting market growth
  • Current market trends 
  • Market structure
  • Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Browse All Market Research Report : http://www.transparencymarketresearch.com/

Tuesday 21 May 2013


Medical practice management software (PMS) assists in managing a healthcare business, starting from the scheduling of patients to the generation of periodic reports. Therefore, selecting the appropriate medical practice management system is crucial in any medical practice. The onus of selecting the practice management software and managing it lies with the IT manager in any healthcare providing institution.


The medical practice management software market helps in integration of electronic health records (EHR), in providing interoperability solutions, and assists in the overall practice management process. The software provides solutions on single database platforms, on multi-tenant SaaS deployed on-premise, and even on cloud platforms. 

The prime factors which invigorate this market are the need for high return on investment, various funding and grants provided by the government, need for better patient-physician coordination, and increase in patient awareness and better health. Choosing the right PMS is a critical task in healthcare management because its functionality greatly determines the overall productivity of the institution in which it is installed. The major challenge faced by PMS users is the time required to completely implement the system in the institution.

The market is set to grow drastically in North America due to government policies in the U.S, especially due to ‘Obamacare’, which makes it compulsory for health care providers to use such software. Europe is the second largest share holder in the global market. With the improvement in the economies of developing countries, Asia is also set to generate huge demand. Some of the major players in medical practice software are Sage Group, NextGen Healthcare, AthenaHealth, eClinicalWorks, MediTouch, and McKesson.
.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 
  • North America 
  • Asia Pacific 
  • Europe
  • Rest of the World  

This report provides comprehensive analysis of 

Market growth drivers 
Factors limiting market growth
Current market trends 
Market structure
Market projections for upcoming years 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 

Browse All Market Research Report : http://www.transparencymarketresearch.com/

Browse : Nondestructive Testing (NDT) Equipment Market : http://www.transparencymarketresearch.com/nondestructive-testing-equipment.html

Browse Bolg : Pharmaceutical Market Research Reports

Thursday 16 May 2013


Antibodies and proteins developed with new and advantageous functions and properties are known as engineering of proteins and antibodies. Protein engineering can be defined as a process of developing valuable proteins and modification of antibodies to increase similarity and is called antibody engineering. Antibody and protein engineering is used in curing inflammatory disorders, as a new treatment of diseases, for protein purification, and in diagnostic procedures. There are two approaches used for designing new antibodies and proteins - directed evolution and rational designing. 


The market for antibody engineering is changing quickly due to novel technologies. Moreover, protein engineering offers flexibility in engineering, and designing new and desirable antibodies is expected to be the major factor driving the growth of the market. The future holds huge opportunities for this market due to the rising prevalence of diseases such as cancer and increasing health care concerns. 

Emerald Bio, ProSci Incorporated, Precision Antibody, Fusion Antibodies, BioXcell, GenTarget Inc, ImaginAb, Covalab, and IBL International are some of the major players in this market.


This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America 
Asia Pacific 
Europe
Rest of the World  

This report provides comprehensive analysis of 

Market growth drivers 
Factors limiting market growth
Current market trends 
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. 


Browse All Market Research Report : http://www.transparencymarketresearch.com/

Tuesday 14 May 2013


Therapeutic vaccines function by triggering a body immune response against a disease. The global therapeutic vaccines market was valued at USD 292 million in 2011. The introduction of therapeutic vaccines has opened up new avenues in the field of chronic disease treatment and prophylactic immunization. Provenge was the first U.S. FDA approved immunotherapy drug to treat prostate cancer in men in 2010, which has encouraged rigorous research and development initiatives by pharmaceutical companies to develop novel vaccines for untapped disease segments.


As a result of these initiatives, many more therapeutic vaccines are currently in the pipeline such as breast cancer vaccine, lung cancer vaccine; Alzheimer’s vaccine, malaria vaccine, and diabetes vaccine are expected to be introduced in the market during the period from 2012 to 2018. 

The market is currently facing growth hindrances as R&D approaches, and regulatory and reimbursement policies are inconspicuous owing to the nascent nature of the market. However, regulatory bodies are working enthusiastically to lay out policies and growth strategies, due to the fact that it holds the potential to solve or curb chronic diseases, with no currently available treatments, such as HIV AIDS.

our components hold imperative importance in designing a therapeutic vaccine:

Antigens: These are substances that evoke an immune response from the body and are responsible for the production of antibodies

Adjuvants: These are immunological agents that help in modifying the effects of a drug or vaccine. Companies are now engaged in designing new adjuvants that will help in enhancing the immunogenicity of an antigen

Cost effective production systems for vaccines

Designing innovative drug delivery devices to enhance vaccine efficacy


The North American therapeutic vaccine market is expected to generate the maximum revenue in the global market during the forecasted period due to the presence of efficient R&D facilities and sophisticated medical infrastructures. The market is segmented into three major application segments namely oncology, infectious diseases and other chronic disorders.

The therapeutic vaccine market with oncology applications market held the majority of the market share in 2011, as most of the research and development exercises are expected to be directed towards this segment during 2012 to 2018.

Merck and GSK have strong therapeutic vaccine product pipelines and are expected to perform better during 2012 to 2018 than their competitors who have fewer products in the pipeline. Some of the other key players of the market include Sanofi-Pasteur, Cytos Biotechnology AG, and Intellect Neurosciences.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include :-

North America ,Asia Pacific ,Europe ,Rest of the World 

Browse All Market Research Report : http://www.transparencymarketresearch.com/
Multiple sclerosis (MS) is an inflammation of fatty myelin sheaths around the axons of the brain and spinal cord. MS tends to affect the ability of nerve cells to communicate with each other in the brain and spinal cord. MS affects people with random symptoms based on the location and severity of attack. One event can last for days, weeks or months and can affect any part of the body. Symptoms include imbalance, loss of motor function, spasms, numbness, incontinence, and difficulty in swallowing.



There is no known cure for the disease currently and the only drugs available in the market are for delaying the progression of the disease. MS is estimated to affect 2.5 million people worldwide with around 5000 new cases developing each year. The National Multiple Sclerosis Society, Multiple Sclerosis Foundation, Multiple Sclerosis Association of America and several others are organizations which are determined to ensure improvement in the lives of affected people to make them more educated and spread awareness of this disease.

Until the last year, the MS drugs market was led primarily by injectables, yet this trend is changing very quickly to give way to oral MS drugs which is expected to grow strongly beginning from 2013. Gilenya and Aubagio are the top current oral drugs in this segment and Biogen’s oral BG-12 and Teva Laquinimod are two other drugs in the pipeline for approval with a significantly higher efficacy to be launched in the next five years. Although oral MS drugs seem to be growing quickly, it is not expected that they would unsettle injectables anytime soon. Several fatal side effects have been linked to use of Gilenya among those who have a heart disease and thus shows that there is still a long way to go for oral MS drugs.


Top contenders in this segment till now are Copaxone, Avonex, Rebif, Betaseron, and Tysabri. Most of these drugs work actively to control MS relapses. Other treatments such as stem-cell transplantation are currently under investigation. The process includes the injection of stem cells which will replace the affected inflamed and diseased cells, greatly improving patient’s quality of life.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include : -

North America, Asia Pacific, Europe, Rest of the World 

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Browse All Market Research Report : http://www.transparencymarketresearch.com/